Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center randomized controlled trial of gemcitabine in combination with gimeracil/oteracil/tegafur compared with gemcitabine alone in patients with advanced nonresectable pancreatic cancer.

Next Previous
X
Search
Trial Profile

Multi-center randomized controlled trial of gemcitabine in combination with gimeracil/oteracil/tegafur compared with gemcitabine alone in patients with advanced nonresectable pancreatic cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms GEMSAP

    • Most Recent Events

    • 18 Jan 2014 Pooled results for prognostic factors from GEST, GEMSAP, and JACCRO PC-01 presented at the 2014 Gastrointestinal Cancers Symposium.
    • 07 Jun 2011 Final overall survival results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2010 Results from first analysis have been presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top